HUP0202621A2 - Formulations for parenteral use of estramustine phosphate with improved pharmacological properties - Google Patents

Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Info

Publication number
HUP0202621A2
HUP0202621A2 HU0202621A HUP0202621A HUP0202621A2 HU P0202621 A2 HUP0202621 A2 HU P0202621A2 HU 0202621 A HU0202621 A HU 0202621A HU P0202621 A HUP0202621 A HU P0202621A HU P0202621 A2 HUP0202621 A2 HU P0202621A2
Authority
HU
Hungary
Prior art keywords
parenteral use
pharmacological properties
formulations
improved pharmacological
estramustine phosphate
Prior art date
Application number
HU0202621A
Other languages
Hungarian (hu)
Inventor
Giovanni Buzzi
Paolo Colombo
Alessandro Martini
Lorena Muggetti
Original Assignee
Pharmacia Italia S.P.A.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacia Italia S.P.A. filed Critical Pharmacia Italia S.P.A.
Publication of HUP0202621A2 publication Critical patent/HUP0202621A2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/42—Proteins; Polypeptides; Degradation products thereof; Derivatives thereof, e.g. albumin, gelatin or zein
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/661—Phosphorus acids or esters thereof not having P—C bonds, e.g. fosfosal, dichlorvos, malathion or mevinphos
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/38—Albumins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36—Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/40—Cyclodextrins; Derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Endocrinology (AREA)
  • Pulmonology (AREA)
  • Reproductive Health (AREA)
  • Dermatology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Immunology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

A találmány javított farmakológiai tulajdonságokkal rendelkező,parenteralis felhasználásra szolgáló ösztramusztingyógyszerkészítményekre, közelebbről parenteralis felhasználásraszolgáló, ciklodextrin-(szulfo-alkil)-étereket és humán albumint istartalmazó ösztramusztin-foszfát gyógyszerkészítményekre vonatkozik. ÓThe invention relates to estramustine medicinal preparations for parenteral use with improved pharmacological properties, more specifically to estramustine phosphate medicinal preparations for parenteral use, which also contain cyclodextrin (sulfoalkyl) ethers and human albumin. HE

HU0202621A 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties HUP0202621A2 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
GBGB9921954.5A GB9921954D0 (en) 1999-09-16 1999-09-16 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
PCT/EP2000/007679 WO2001019338A1 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Publications (1)

Publication Number Publication Date
HUP0202621A2 true HUP0202621A2 (en) 2002-12-28

Family

ID=10861066

Family Applications (1)

Application Number Title Priority Date Filing Date
HU0202621A HUP0202621A2 (en) 1999-09-16 2000-08-03 Formulations for parenteral use of estramustine phosphate with improved pharmacological properties

Country Status (20)

Country Link
EP (1) EP1212040A1 (en)
JP (1) JP2003509355A (en)
KR (1) KR20020059405A (en)
CN (1) CN1177583C (en)
AU (1) AU777763B2 (en)
BR (1) BR0014063A (en)
CA (1) CA2385063A1 (en)
CZ (1) CZ2002943A3 (en)
EA (1) EA005308B1 (en)
GB (1) GB9921954D0 (en)
HK (1) HK1047227A1 (en)
HU (1) HUP0202621A2 (en)
IL (1) IL148409A0 (en)
MX (1) MXPA02002859A (en)
NO (1) NO20021306L (en)
NZ (1) NZ517631A (en)
PL (1) PL353954A1 (en)
SK (1) SK3452002A3 (en)
WO (1) WO2001019338A1 (en)
ZA (1) ZA200201743B (en)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658913B2 (en) 2005-11-28 2010-02-09 Verrow Pharmaceuticals, Inc. Compositions useful for reducing nephrotoxicity and methods of use thereof
WO2012037704A1 (en) 2010-09-21 2012-03-29 Telefonaktiebolaget L M Ericsson (Publ) Air-interface timing synchronization sharing
WO2019094819A2 (en) * 2017-11-09 2019-05-16 Abon Pharmaceuticals, Llc Intravenous delivery systems for chemotherapy drugs

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS59108800A (en) * 1982-12-13 1984-06-23 Japan Atom Energy Res Inst Fine particle having guided missile action and slow-releasing function of carcinostatic agent
KR0166088B1 (en) * 1990-01-23 1999-01-15 . Derivatives of cyclodextrins exhibiting enhanced aqueous solubility and the use thereof
US5602112A (en) * 1992-06-19 1997-02-11 Supergen, Inc. Pharmaceutical formulation
GB9419153D0 (en) * 1994-09-22 1994-11-09 Erba Carlo Spa Estramustine formulations with improved pharmaceutical properties
US20020039594A1 (en) * 1997-05-13 2002-04-04 Evan C. Unger Solid porous matrices and methods of making and using the same

Also Published As

Publication number Publication date
IL148409A0 (en) 2002-09-12
CA2385063A1 (en) 2001-03-22
JP2003509355A (en) 2003-03-11
NZ517631A (en) 2004-01-30
KR20020059405A (en) 2002-07-12
EA005308B1 (en) 2004-12-30
NO20021306L (en) 2002-04-24
AU6836300A (en) 2001-04-17
MXPA02002859A (en) 2003-07-21
GB9921954D0 (en) 1999-11-17
HK1047227A1 (en) 2003-02-14
BR0014063A (en) 2004-06-29
AU777763B2 (en) 2004-10-28
EP1212040A1 (en) 2002-06-12
CN1177583C (en) 2004-12-01
CZ2002943A3 (en) 2002-08-14
CN1374858A (en) 2002-10-16
NO20021306D0 (en) 2002-03-15
SK3452002A3 (en) 2002-08-06
EA200200369A1 (en) 2002-08-29
PL353954A1 (en) 2003-12-15
ZA200201743B (en) 2003-05-28
WO2001019338A1 (en) 2001-03-22

Similar Documents

Publication Publication Date Title
WO2001026693A3 (en) Manufacture of polyglutamate-therapeutic agent conjugates
AU2002305099A1 (en) Fatty alcohol drug conjugates
CA2119154A1 (en) Derivatives of Cyclodextrins Exhibiting Enhanced Aqueous Solubility and the Use Thereof
MY125978A (en) Admantane derivatives
WO2001070275A3 (en) Polyglutamic acid-camptothecin conjugates and methods of preparation
EE200000378A (en) Adamantane derivatives
PL360941A1 (en) Topical composition containing at least one vitamin d or one vitamin d analogue and at least one corticosteroid
DE60032789D1 (en) MICROSTRUCTURE STENT STRUCTURE
AU2002366042A1 (en) Solid dispersions containing substituted cyclodextrin and insoluble drug and their preparations
AP9901534A0 (en) Pharmaceutical formulations.
MXPA02008801A (en) Indole derivatives, process for preparation of the same and use thereof.
SG146442A1 (en) Sulphonamide derivatives, their preparation and use as medicaments
CA2294783A1 (en) Pharmaceutical compositions for oral administration, comprising an active substance and a cyclodextrin
AU4155897A (en) Cytotoxic amino sugar and related sugar derivatives of indolopyrrolocarbazoles
AU5186799A (en) Peptides of il-2 and derivatives thereof and their use as therapeutic agents
HK1030885A1 (en) The use of isatin and oxindole derivatives in the preparation of a medicament for use in the treatment of mycobacterial disease
AU2003297199A1 (en) Human chondroitinase glycoprotein (chasegp), process for preparing the same, and pharmaceutical compositions comprising thereof
PT1107793E (en) DEXTRANE-LEPTIN CONJUGATES, PHARMACEUTICAL COMPOSITIONS AND RELATED PROCESSES
HUP0202729A2 (en) Compositions for parenteral use of estramustine phosphate and amino acids
HUP0202621A2 (en) Formulations for parenteral use of estramustine phosphate with improved pharmacological properties
HUP0300185A2 (en) Formulations for parenteral use of estramustine phosphate and sulfoalkyl ether cyclodextrins
EP1273301A3 (en) Pharmaceutical preparations based on active ingredients susceptible to illict administration
AP2001002369A0 (en) Pharmaceutical complex.
MD1473G2 (en) Antiherpetic remedy
DE69818492D1 (en) 7-methylthiooxomethyl- und 7-methylthiodioxomethyl-paclitaxele